Comparison of Different Methods of CAPTure of Circulating Tumour Cells (CTC) in Patients With Metastatic Breast or Prostate Cancer

This trial is a pilot, prospective, single-center study conducted in a population of patients with metastatic breast cancer (whatever the immunohistochemical subtype) or metastatic prostate cancer. The aim of this exploratory study is to compare the sensitivity of three different techniques (CellSearch®, Parsortix® and SmartCatch®) in detecting circulating tumor cells (CTCs). After the patient's agreement, and before starting anti-tumor treatment, a blood sample will be taken using the 3 different CTC detection techniques. Each patient will participate in the study for one day. A total of 54

Trial Details

NCT ID
NCT06904625
Phase
NA
Sponsor
Institut Claudius Regaud
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Taking blood samples before starting treatment
Locations (sample)
  • Toulouse, France|43.60426,1.44367

Key Eligibility Criteria

  • Patient with breast cancer (whatever the immunohistochemical subtype: triple-negative, RH+/HER2-negative or HER2-positive) or prostate cancer, mult…
  • Patient not yet initiated on a new specific treatment for breast or prostate cancer at inclusion.
  • Age ≥ 18 years and WHO ≤ 2
  • Patient affiliated to Social Security scheme in France.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →